$MGNX News
Last published 8h ago
- 8h agoMGNXMACROGENICS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 8h agoMGNXMacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate ProgressGlobeNewswireROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended September 30, 2026, and highlighted recent corporate progress.
- 1d agoMGNXSTIFEL 2026 HEALTHCARE CONFERENCE - MACROGENICS INCEarnings Call Transcriptsmyself. Anyway, thanks everyone for being here. Very glad to have with us for the next discussion, the CEO of Macrogenics, Eric Grisser. We're going to have a casual chat. If anyone has a question, feel free to raise you
- 1w agoMGNXMacroGenics to Participate in Upcoming Investor ConferencesGlobeNewswireROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
- 1w agoMGNXMacroGenics to Participate in Upcoming Investor ConferencesGlobeNewswireROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing...
- 1w agoMGNXMacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of DirectorsGlobeNewswireROCKVILLE, MD, Nov. 03, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
- 2w agoMGNXMacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic CancerGlobeNewswireSingle agent lorigerlimab demonstrated encouraging preliminary clinical activity in clear cell gynecologic cancer (CCGC) with a confirmed ORR of 25% and a DCR of 44%Safety profile was manageable; further dose
- 2w agoMGNXMacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHNGlobeNewswireDurable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN
- 4w agoMGNXMacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsGlobeNewswireROCKVILLE, MD, Oct. 15, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
- 2mo agoMGNXMacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced
- 3mo agoMGNXMacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial PositionGlobeNewswireAnnounced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipelineData presentations
- 3mo agoMGNXMacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026GlobeNewswireInterim Phase 1 results accepted for poster presentation at ESMO Congress 2026Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per
- 4mo agoMGNXBORAYMacroGenics Completes Sale of GMP Manufacturing Operations to Bora PharmaceuticalsGlobeNewswireROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
- 4mo agoMGNXMacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® ApprovalGlobeNewswireROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
- 6mo agoMGNXMacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology ForumGlobeNewswireROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced
- 6mo agoMGNXMacroGenics Reports First Quarter 2026 Financial Results and Highlights Business TransformationGlobeNewswireManufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and developmentManufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide up to $202.5
- 6mo agoBORAYMGNXMacroGenics to Sell GMP Manufacturing Operations to Bora PharmaceuticalsGlobeNewswire•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD, May 11, 2026 (GLOBE
- 6mo agoMGNXMacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase AgreementGlobeNewswireROCKVILLE, MD, May 04, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
- 7mo agoMGNXFDA Removes Partial Clinical Hold on MacroGenics' LINNET StudyGlobeNewswire• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX),
- 8mo agoMGNXMacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data DisclosuresGlobeNewswireInitial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026Lorigerlimab Phase 2 LINNET study update in mid-2026IND submission for MGC030, a first-in-class
- 8mo agoMGNXMacroGenics to Participate in Upcoming Investor ConferencesGlobeNewswireROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced
- 8mo agoMGNXMacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET TrialGlobeNewswireROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
- 11mo agoMGNXMacroGenics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswireROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced
- 1y agoMGNXMacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate ProgressGlobeNewswireAchieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platformRealigned pipeline
- 1y agoMGNXMacroGenics to Participate in the Stifel 2025 Healthcare ConferenceGlobeNewswireROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced
- 1y agoMGNXMacroGenics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced
- 1y agoMGNXMacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic PrioritiesGlobeNewswireNewly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ®
- 1y agoMGNXMacroGenics Appoints Eric Risser as President and Chief Executive OfficerGlobeNewswireROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today
- 1y agoMGNXMacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase AgreementGlobeNewswireMacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard)MacroGenics' cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) --
- 1y agoMGNXMacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025GlobeNewswireROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics
- 1y agoMGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial ResultsGlobeNewswireFirst patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in
- 1y agoMGNXMacroGenics Announces Date of First Quarter 2025 Financial ResultsGlobeNewswireROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics
- 1y agoMGNXMacroGenics to Participate in Upcoming Investor ConferenceGlobeNewswireROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics
- 1y agoMGNXMacroGenics Provides Update on Corporate Progress and 2024 Financial ResultsGlobeNewswireFully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple
- 1y agoMGNXMacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference CallGlobeNewswireROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics
- 1y agoMGNXMacroGenics to Participate in Upcoming Investor ConferencesGlobeNewswireROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics
- 1y agoMGNXApproval of Margenza, Bla #761150FDA Approved DrugsApproval Date: 01/15/2025; Drug Name: Margenza, Bla #761150; Active Ingredients: MARGETUXIMAB-CMKB; Company: Macrogenics Inc; Submission Status: Approval; Application Number: 761150
- 1y agoMGNXMacroGenics to Participate in Upcoming Investor ConferenceGlobeNewswireROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal
- 2y agoMGNXMacroGenics to Participate in Upcoming Investor ConferencesGlobeNewswireROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics
- 2y agoMGNXMacroGenics, Inc. (MGNX) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoMGNXMacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial ResultsGlobeNewswireStrengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed ADC
- 2y agoMGNXMacroGenics Announces Leadership TransitionGlobeNewswireScott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical
- 2y agoMGNXMacroGenics Announces Date of Third Quarter 2024 Financial Results Conference CallGlobeNewswireROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the
- 2y agoMGNXMacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®Business WireMacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera
- 2y agoMGNXShareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNXGlobeNewswireNEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ:MGNX). Shareholders who purchased shares of MGNX during the class period listed
- 2y agoMGNXDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenicsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MacroGenics To Contact Him Directly To Discuss Their Options If you suffered
- 2y agoMGNXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics Lawsuit - MGNXPR NewswireThe Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during...
- 2y agoMGNXMacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024GlobeNewswireEncouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of
- 2y agoMGNXINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenicsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against MacroGenics, Inc. ("MacroGenics" or the...
- 2y agoMGNXMacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024GlobeNewswireROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based